Fujirebio Europe updates its market-leading INNO-LIA® Score strip portfolio

Product news

Gent, Belgium: August 13 2014 - Fujirebio Europe releases updates of its market-leading  INNO-LIA® Score immunoblot product range  and the associated LiRAS® for Infectious Diseases software for automated interpretation of results. The improvement of the antibody confirmation assays confirms Fujirebio Europe's strong position as one of the world leaders in strip-based diagnostics solutions.

“Our INNO-LIA® Score line immuno-assays have been appreciated through its outstanding performance in clinical laboratories and blood banks across the world for several years now. Based on customer feedback we have added product-specific identifiers to the strips and also improved the interpretation criteria for INNO-LIA® HIV I/II Score. With these important updates of our portfolio we can now offer our customers products with improved traceability and, specifically for INNO-LIA® HIV I/II Score, an even better classification of the HIV-type.”, said Christiaan De Wilde, CEO at Fujirebio Europe. “We know that our customers will appreciate these product upgrades which confirm the strong position that our INNO-LIA® Score portfolio holds in the market of antibody confirmation.”

The product updates concern the INNO-LIA® HIV I/II Score assay (for confirming the presence of antibodies against the human immunodeficiency virus type 1 (HIV-1), including group O, and type 2 (HIV-2) and differentiation between HIV-1 and HIV-2 infections), the INNO-LIA® HCV Score assay (for detection of antibodies to human hepatitis C virus), the INNO-LIA® Syphilis Score assay (for confirming the presence of antibodies against Treponema pallidum), the INNO-LIA® HTLV I/II Score assay (for confirmation and discrimination of human T-cell lymphotrophic virus type I (HTLV I) and type II (HTLV II) infections) and are also fully implemented in the interpretation software package LiRAS® for Infectious Diseases.

Please contact your local sales representative for the availability of these products in your country.

 
About Fujirebio

Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.